Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Chapel Hill, USA
Exchange East, Suite 212
1450 Raleigh Road
Chapel Hill, NC, 27517
USA

People

President and CEO
Board Member
director
Chief Scientific Officer

Funding

TOTAL $66.5M
FUNDING TOTAL $66.5M
Series A, 12/2006
The Aurora Funds
New Enterprise Associates
$14.5M
Venture Round, 8/2009
$9M
Venture Round, 8/2010
$15M
Series B, 11/2012
OrbiMed Advisors
New Enterprise Associates
The Aurora Funds
Osage University Partners
$28M

Tags

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don’t exist, are ineffective or are inadequate.

Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company’s core nitroxyl platform has generated several pre-clinical and clinical candidates including the company’s lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.

Recent Milestones

Videos

Screenshots

Cardioxyl Pharmaceuticals screenshot
Above: Cardioxyl Pharmaceuticals
Uploaded: 3/13/13

Sources

  1. Cardioxyl Raises 14.5MM Series A Financing (cardioxyl.com) [edit]
  2. SEC (sec.gov) [edit]
  3. SEC (sec.gov) [edit]
  4. Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors (cardioxyl.com) [edit]
Edit This Page
Last Edited 3/8/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy